Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-622-4003
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees38
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Zafgen (NASDAQ:ZFGN) Frequently Asked Questions
What is Zafgen's stock symbol?
Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."
How were Zafgen's earnings last quarter?
Zafgen Inc (NASDAQ:ZFGN) announced its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.06. View Zafgen's Earnings History.
When is Zafgen's next earnings date?
What price target have analysts set for ZFGN?
7 Wall Street analysts have issued 12-month target prices for Zafgen's shares. Their predictions range from $0.78 to $17.00. On average, they expect Zafgen's share price to reach $7.06 in the next year. This suggests a possible upside of 859.5% from the stock's current price. View Analyst Price Targets for Zafgen.
What is the consensus analysts' recommendation for Zafgen?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zafgen.
Has Zafgen been receiving favorable news coverage?
News stories about ZFGN stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Zafgen earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Zafgen.
Are investors shorting Zafgen?
Zafgen saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 701,000 shares, an increase of 60.6% from the August 30th total of 436,600 shares. Based on an average daily volume of 526,900 shares, the short-interest ratio is presently 1.3 days. Currently, 2.1% of the shares of the stock are short sold. View Zafgen's Current Options Chain.
Who are some of Zafgen's key competitors?
Some companies that are related to Zafgen include PhaseBio Pharmaceuticals (PHAS), Scpharmaceuticals (SCPH), IDEAYA Biosciences (IDYA), Paratek Pharmaceuticals (PRTK), OASMIA PHARMACE/ADR (OASM), Abeona Therapeutics (ABEO), Adamas Pharmaceuticals (ADMS), Fulcrum Therapeutics (FULC), Menlo Therapeutics (MNLO), Strongbridge Biopharma (SBBP), Eton Pharmaceuticals (ETON), Helix Biopharma (HBPCF), Corvus Pharmaceuticals (CRVS), Correvio Pharma (CORV) and Aptinyx (APTX).
What other stocks do shareholders of Zafgen own?
Who are Zafgen's key executives?
Zafgen's management team includes the folowing people:
- Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)
- Ms. Patricia L. Allen, Chief Financial Officer (Age 57)
- Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)
- Dr. James E. Vath, Head of Discovery & Devel. (Age 58)
- Mr. Brian P. McVeigh, Chief Bus. Officer (Age 46)
Who are Zafgen's major shareholders?
Which major investors are buying Zafgen stock?
How do I buy shares of Zafgen?
Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zafgen's stock price today?
One share of ZFGN stock can currently be purchased for approximately $0.74.
How big of a company is Zafgen?
Zafgen has a market capitalization of $27.50 million. The biopharmaceutical company earns $-61,370,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 38 workers across the globe.View Additional Information About Zafgen.
What is Zafgen's official website?
How can I contact Zafgen?
Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]
MarketBeat Community Rating for Zafgen (NASDAQ ZFGN)
MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe ZFGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
